Roche : new up leg in sight ?
Nicolas Suiffet June 19, 2020 3:33 PM
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS).
Roche, the pharmaceutical giant, said a phase 3 study, evaluating its ipatasertib in combination with abiraterone and prednisone/prednisolone, met the co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer, but the other co-primary endpoint of rPFS in the overall study population was not met.
From a chartist's point of view, the short term consolidation started in May could be over as prices have landed on a key support at 320CHF and are posting a rebound. The breakout confirmation of the 20DMA is a bullish event. The daily Relative Strength Index (RSI, 14) is pushing above its declining trend line. The general up trend remains in place.
Readers may want to consider the potential for long positions above the horizontal support at 320CHF with 351CHF and 358CHF as targets. Alternatively, a break below 320CHF would invalidate the bullish trend and would call for a down move towards 298CHF.
Source: GAIN Capital, TradingView
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.
Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.
Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.